A Phase 1 interventional study of IV administration of CG-BM1 and Placebo in Ankylosing Spondylitis, sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.
Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 54th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 12 of the 22 other live ones, and was the 73rd registered.
535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.
Browse Spondylitis, Ankylosing studies →20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Huabo Biopharm Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–70
China-Japan Friendship Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 22 · Phase 4 17
First in 2005; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 87 across 304 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 150 across the 62 interventional studies, 400 across the 15 observational. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 77 have an industry lead sponsor. The 10 most frequent:
Eighth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
Eighth Affiliated Hospital, Sun Yat-sen University has 1 study filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
9 of the studies in Spondylitis, Ankylosing with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237568Phase 3Lynk Pharmaceuticals Co., LtdA Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | 2026-11 |
| NCT06000956Phase 3Tasly Pharmaceutical Group Co., LtdA Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | 2026-12-01 |
| NCT07261644Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | 2027-01-14 |
| NCT07172360Phase 3Jiangsu vcare pharmaceutical technology co., LTDEfficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | 2027-08-30 |
| NCT07920861Huabo Biopharm Co., Ltd.A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Spondylitis, Ankylosing with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if allogeneic human bone marrow-derived mesenchymal stem cells (CG-BM1) are safe and show preliminary efficacy in treating patients with ankylosing spondylitis (AS). It will also explore the appropriate dose of CG-BM1.
The main questions it aims to answer are:
What medical problems (adverse events) do participants have when taking CG-BM1? (Safety and tolerability)
Does CG-BM1 improve disease activity, pain, and function in patients with AS? (Preliminary efficacy)
Researchers will compare CG-BM1 to a placebo (an inactive substance that looks like CG-BM1) in the second phase of the study to see if CG-BM1 works for AS.
This study has two phases:
Phase 1 (dose-escalation): Open-label, single-arm. Participants will receive one of three escalating doses of CG-BM1 weekly for 4 weeks.
Phase 2 (dose-expansion): Randomized, double-blind, placebo-controlled. Participants will receive either the recommended dose of CG-BM1 or a placebo weekly for 4 weeks, in addition to standard background therapy (celecoxib).
Participants will:
Receive CG-BM1 or placebo via intravenous infusion once a week for 4 weeks
Visit the clinic for follow-up assessments at Week 1, 4, 8, 12, and 24 after the first infusion
Undergo physical exams, laboratory tests (blood and urine), and complete questionnaires about disease activity, pain, and function (e.g., BASDAI, VAS, ASAS response criteria)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be sequentially assigned to one of three dose cohorts using a "3+3" design: low-dose (1\*10\^6 cells/kg), medium-dose (2.0\*10\^6 cells/kg), or high-dose 4.0\*10\^6 cells/kg). In each cohort, CG-BM1 will be administered via intravenous infusion once weekly for a total of 4 doses on Days 0, 7, 14, and 21. All participants across all cohorts will concurrently receive standard background therapy consisting of celecoxib 0.2g orally once daily.
Biological: IV administration of CG-BM1
Participants will be randomized to receive the placebo (Compound Electrolyte Injection) via intravenous (IV) infusion once weekly for a total of 4 doses, mimicking the regimen of the experimental group. All participants will simultaneously receive a background therapy of celecoxib 0.2g orally once daily.
Biological: Placebo
Participants will be randomized to receive CG-BM1 at the clinically recommended dose (determined by the Safety Review Committee based on Phase 1 results) via intravenous (IV) infusion once weekly for a total of 4 doses. All participants will simultaneously receive a background therapy of celecoxib 0.2g orally once daily.
Biological: CG-BM1
Dose level 1: CG-BM1 1.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily Dose level 2: CG-BM1 2.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily Dose level 3: CG-BM1 4.0×10⁶ cells/kg, IV, weekly × 4 + celecoxib, 0.2g, p.o. daily
Sodium Chloride Solution, 5 ml, IV, weekly × 4+ celecoxib, 0.2g, p.o. daily
CG-BM1 \[recommended dose\], IV, weekly × 4 + celecoxib, 0.2g, p.o. daily
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: 24 weeks
Incidence of Dose-Limiting Toxicities (DLTs)
Time frame: 24 weeks
Percentage of Participants Achieving ASAS20 Response
ASAS20 response is defined as an improvement of \> 20% and an absolute improvement of \> 1 unit (on a 0-10 scale) or \> 10 mm (on a 0-100 mm scale) in at least 3 of the following 4 domains: Patient Global Assessment, Physical Function (BASFI), Total Spinal Pain, and Inflammation (Morning Stiffness). Additionally, there must be no worsening in the remaining domain.
Time frame: Weeks 1, 4, 8, 12, and 24
Global Assessment of Disease Activity
Evaluated using a 0-10 Visual Analog Scale (VAS), where 0 indicates "not active" and 10 indicates "very active". Higher scores represent greater disease activity. The outcome will report the change from baseline values at each subsequent visit timepoint.
Time frame: Weeks 1, 4, 8, 12, and 24
Total Spinal Pain Intensity Score
Measured by a Visual Analog Scale (VAS) ranging from 0 mm (no pain) to 100 mm (severe pain), calculating the average score of overall spinal pain and nocturnal spinal pain over the past week. Higher scores represent worse pain intensity.
Time frame: Weeks 1, 4, 8, 12, and 24
Bath Ankylosing Spondylitis Functional Index (BASFI)
BASFI consists of 10 items assessing the patient's ability to perform specific activities of daily living. Each item is scored on a 0-10 scale (0 = easy, 10 = impossible). The total score is calculated as the mean of the 10 scores, where a higher score indicates more severe functional impairment.
Time frame: Weeks 1, 4, 8, 12, and 24
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
BASDAI evaluates 6 items: fatigue, spine pain, peripheral joint pain, localized tenderness, morning stiffness severity, and morning stiffness duration over the past week, each on a 0-10 scale. The final score is calculated as the average of the first 4 items plus the average of the two morning stiffness items, with a total range of 0 to 10. Higher scores indicate more severe disease activity.
Time frame: Weeks 1, 4, 8, 12, and 24
Bath Ankylosing Spondylitis Metrology Index (BASMI)
BASMI evaluates spinal mobility based on 5 clinical measurements: cervical rotation, tragus-to-wall distance, lumbar flexion (modified Schober's test), lumbar side flexion, and intermalleolar distance. Each component is scored linearly from 0 to 2, with a total composite score ranging from 0 to 10. Higher scores indicate more severe impairment of spinal mobility.
Time frame: Weeks 1, 4, 8, 12, and 24
Swollen Joint Count(SJC) and Tender Joint Count(TJC) Based on 44-Joint Assessment
Peripheral arthritis progression will be evaluated via the standard 44-joint count assessment. Scores range from 0 to 44 joints, where a reduction in count indicates therapeutic improvement.
Time frame: Weeks 1, 4, 8, 12, and 24
Serum C-reactive Protein (CRP) Concentration (mg/L)
Evaluated via peripheral blood samples to explore the systemic anti-inflammatory effect of CG-BM1.
Time frame: Weeks 1, 4, 8, 12, and 24
Erythrocyte Sedimentation Rate (ESR) (mm/h)
Evaluated via peripheral blood samples to explore the systemic anti-inflammatory effect of CG-BM1.
Time frame: Weeks 1, 4, 8, 12, and 24
Serum Concentrations of Cytokines (TNF-α and BMP2) (pg/mL)
Measured via enzyme-linked immunosorbent assay (ELISA) from collected serum samples to investigate the mechanistic pathways of bone remodeling and immune regulation.
Time frame: Weeks 1, 4, 8, 12, and 24
Peripheral Blood Immune Cell Subset Percentages
Evaluated via multicolour flow cytometry to quantify the percentages of CD4+ T cells, CD8+ T cells, Treg cells, Th17 cells, NK cells, MAIT cells, monocytes, neutrophils, and B cells relative to total lymphocytes or leukocytes, in order to track immune homeostasis reconstruction.
Time frame: Weeks 1, 4, 8, 12, and 24
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eighth Affiliated Hospital, Sun Yat-sen University